NatureCell "MFDS Rejects Domestic Phase 1/2a Clinical Trial Plan for COVID-19 Pneumonia Treatment"
[Asia Economy Reporter Ji Yeon-jin] Bio-pharmaceutical company Naturecell announced on the 3rd that the Ministry of Food and Drug Safety rejected the domestic Phase 1/2a clinical trial plan to explore the safety and efficacy of the allogeneic adipose-derived mesenchymal stem cell therapy AstroStem-V in pneumonia patients caused by COVID-19 infection.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051414165763158_1778735817.jpg)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- "It's Only May, but Convenience Stores Know... Iced Americano at 24°C, Tube Ice Cream at 31°C: The Thermometer of the Summer Sales Boom"
- Mother of Three Gang-Raped on Bus in India... Outrage as Bus Driver Implicated
- "I Hated Myself as Much as I Craved It"... Even a Mother's Tears and Brilliant Dreams Were Shattered [ChwiYakGukga] ⑦
The company explained, "We received a request from the Ministry of Food and Drug Safety to supplement the data for the clinical trial plan of AstroStem-V, and we prepared and submitted the related materials, but it was rejected due to insufficient data on some items."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
